Sinopharm Group Co (FRA:X2S) LT-Debt-to-Total-Asset : 0.05 (As of Jun. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Sinopharm Group Co's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.05.

Sinopharm Group Co's long-term debt to total assets ratio increased from Jun. 2023 (0.04) to Jun. 2024 (0.05). It may suggest that Sinopharm Group Co is progressively becoming more dependent on debt to grow their business.

Sinopharm Group Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Sinopharm Group Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co LT-Debt-to-Total-Asset Chart

Sinopharm Group Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.04

0.05

0.03

Sinopharm Group Co Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.04	0.04	0.05	0.05	0.03

Sinopharm Group Co LT-Debt-to-Total-Asset Calculation

Sinopharm Group Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	2216.006	/	49238.547
	=	0.05

Sinopharm Group Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	2510.602	/	55010.23
	=	0.05

Sinopharm Group Co (FRA:X2S) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Sinopharm Group Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinopharm Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (FRA:X2S) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

SHTDY:USA SHTDF:USA 01099:Hong Kong

Address

No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023

Website

http://www.sinopharmgroup.com.cn

Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2023. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.

Sinopharm Group Co Headlines

No Headlines